eXoZymes (NASDAQ:EXOZ) Posts Earnings Results

eXoZymes (NASDAQ:EXOZ) announced its quarterly earnings results on Thursday. The company reported ($0.33) earnings per share for the quarter, Zacks reports.

eXoZymes Trading Up 3.3%

Shares of EXOZ traded up $0.20 during mid-day trading on Friday, hitting $6.20. The company had a trading volume of 4,541 shares, compared to its average volume of 7,073. eXoZymes has a 1-year low of $4.35 and a 1-year high of $18.40. The business’s 50-day simple moving average is $6.60 and its 200-day simple moving average is $8.42. The stock has a market cap of $57.07 million, a PE ratio of -5.48 and a beta of 2.93. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.03.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of eXoZymes in a research report on Friday, May 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

About eXoZymes

eXoZymes, Inc develops, manufactures and supplies a range of enzymes and reagents designed for molecular biology research and diagnostic applications. The company’s enzyme engineering platform underpins a portfolio of products aimed at supporting nucleic acid purification, amplification and analysis workflows.

Key offerings from eXoZymes include magnetic bead–based nucleic acid extraction kits, DNA polymerases, reverse transcriptases, proteases and custom enzyme services. In addition, the company provides molecular diagnostic test kits designed for pathogen detection, leveraging scalable production processes and quality systems aligned with regulatory standards.

eXoZymes serves academic research institutions, biotechnology and pharmaceutical companies, and clinical diagnostic laboratories worldwide.